- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00686985
Docetaxel - Carboplatin as Second Line Treatment in Patients With Small Cell Lung Cancer (DOCAR)
A Phase II Study of Docetaxel - Carboplatin as Second Line Treatment in Patients With Refractory or Relapsed Small Cell Lung Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background:
Small cell lung cancer (SCLC) is diagnosed in approximately 15 % of all the lung cancer cases. SCLC is recognized by its rapid tumor growth, with a high chemo- and radio sensitivity, and by its high metastasizing potential. Patients with extensive-stage disease have a 5-year survival rate of 1% to 2%.
Almost 2/3 of the patients have already extensive disease (ED) upon diagnosis.The recommended treatment of ED-SCLC is systemic chemotherapy, considered to be the standard first line treatment option in all patients with SCLC regardless of performance status and age. World-wide, the most commonly used regimen for 1st line treatment is the combination of cisplatin-etoposide, while in the Netherlands the cyclophosphamide, doxorubicin and etoposide regimen is widely used.Survival outcome with these regimens appear similar.
Unfortunately, relapses occur in all patients and responses to second-line chemotherapy have proven to be of short term. Until recently, there were no registered drugs for treatment of relapsing SCLC. Phase II studies with docetaxel in first line - and second line treatment of SCLC demonstrated that docetaxel is an active agent in these patient groups. Therefore docetaxel seems suitable for evaluation in combination with other cytotoxic drugs active in this disease. Until now no studies have been performed with a combination of docetaxel and platinum in this group of previously treated SCLC patients.
A phase II study in previously untreated patients with SCLC shows that the combination docetaxel and cisplatin/carboplatin is an active and well tolerated regimen in extensive SCLC.
Study objectives:
To evaluate the anti-tumor activity of a docetaxel/carboplatin regimen in patients with refractory or relapsed SCLC. Furthermore to asses the safety profile of the docetaxel/carboplatin combination.
Trial design:
This study will be a open label non-randomized study conducted in patients with refractory or relapsed SCLC. It is a phase II study with 50 patients.
Docetaxel infusion 75 mg/m2, carboplatin AUC = 6 mg/ml·min day 1, every 21 days for 4-6 cycles.
Population:
Patients with histologically or cytologically proven SCLC at the first diagnosis with refractory or relapsed SCLC after first line treatment. Signed informed consent. Age > 18 years. WHO ps 0,1 or 2.
Endpoints:
Primary endpoint: response rate. Secondary endpoint(s): time to progression, response duration, safety profile and survival.
Stress and risks for the patient:
Hospital visits and tests are not different from the standard treatment. Stress due to adverse events is not essential higher estimated. Special risks are not expected. Frequently medical examination and control of laboratory results will be done. Detailed instruction will be given about what do to in case of serious toxicity.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: B Biesma, Dr.
- Phone Number: 31-073-699-2615
- Email: b.biesma@jbz.nl
Study Contact Backup
- Name: F.M.N.H. Schramel, Dr.
- Phone Number: 31-030-609-3459
- Email: f.schramel@antonius.net
Study Locations
-
-
Brabant
-
's-Hertogenbosch, Brabant, Netherlands, 5211NL
- Recruiting
- B. Biesma
-
Contact:
- B. Biesma, Dr.
- Phone Number: 31-073-699-2615
- Email: b.biesma@jbz.nl
-
Contact:
- F. Schramel, Dr.
- Phone Number: 31-0609-9111
- Email: f.schramel@antonius.net
-
Sub-Investigator:
- H van der Heijden, Dr.
-
Sub-Investigator:
- J.N.H. Timmer - Bonte, Dr.
-
Sub-Investigator:
- H Smit, Dr.
-
Sub-Investigator:
- H.J.M. Groen, Prof. Dr.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically or cytologically proven SCLC at the first diagnosis
- Refractory or relapsed SCLC
- Measurable disease according to RECIST criteria
- There must be a minimum of 2 weeks between the end of prior radiotherapy and study entry. (No more than 30% of available bone marrow should have been irradiated as recommended by the RTOG).
- Patients must have fully recovered from toxic effects of previous antitumor therapy.
- Age > 18 years.
- WHO performance status 0- 2 (Appendix II).
Hb > 6.0 mmol/L,
- Neutrophils > 1.5 x 109/L,
- Platelets > 100 x 109/L·
- Total bilirubin < the upper-normal limits of the institutional normal values.
- ALAT (SGPT), ASAT (SGOT) < 2.5 times the upper-normal limits of the institutional normal values.
- Alkaline Phosphatase < 5 times the upper-normal limits of the institutional normal values. If AP > 2.5 x ULN then ALAT and ASAT must be <1.5 x ULN, otherwise, the patient is not eligible
- Creatinine < 140 mmol/L; or creatinine clearance according to Cockcroft formula >50 ml/min·
- Signed informed consent prior to beginning protocol specific procedures
Exclusion Criteria:
- More than one line of chemotherapy for metastatic disease
- Treatment with a platinum compound during the last 3 months before randomisation
- Pregnant or lactating women or women of childbearing potential not adhering to adequate anticonceptive measures
- Evidence of (other) active invasive malignancy other than non-melanoma skin cancer.
- Clinical evidence CNS metastases.
- Symptomatic peripheral neuropathy > grade 2 according (NCI CTC, Appendix III)Definite contraindications for the use of corticosteroids
- Concurrent treatment with other experimental drugs.
- Participation in another clinical trial with any investigational drug within 30 days prior to study screening.
- Concurrent treatment with any other cytotoxic anti-cancer therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A
|
Carboplatin AUC 5, Docetaxel 75 mg/m2, q 3 weeks, 4-6 cycles, 12-18 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Response rate
Time Frame: 2 yrs
|
2 yrs
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to progression; Response duration; Survival; Safety profile
Time Frame: 2 yrs
|
2 yrs
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: B Biesma, Dr., Jeroen Bosch Ziekenhuis
Study record dates
Study Major Dates
Study Start
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Small Cell Lung Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Docetaxel
- Carboplatin
Other Study ID Numbers
- DOCAR study
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Small Cell Lung Cancer
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung CancerUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedTobacco Use Disorder | Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Limited Stage Small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB...United States
-
Washington University School of MedicineMerck Sharp & Dohme LLCWithdrawnNSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Small Cell Lung Extensive Stage
-
Shanghai Chest HospitalRecruitingSmall Cell Lung Carcinoma | Small-cell Lung Cancer | Small Cell Lung Cancer Limited Stage | Small Cell Lung Cancer Extensive Stage | Small Cell Lung Cancer, Combined TypeChina
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
Clinical Trials on Carboplatin, docetaxel
-
Chinese PLA General HospitalUnknownNeoplasms, Therapy-AssociatedChina
-
Zhenzhen LiuRecruitingBreast Cancer | Triple Negative Breast Cancer | CamrelizumabChina
-
University College London HospitalsCompletedBreast Cancer | Hereditary Breast/Ovarian Cancer (brca1, brca2) | brca1 Mutation Carrier | brca2 Mutation CarrierAustralia, Israel, United Kingdom, Spain, Sweden, Portugal
-
Miguel Martín JiménezUNC Lineberger Comprehensive Cancer Center; Hospital Universitario Ramon y... and other collaboratorsActive, not recruitingBreast Cancer | Breast Cancer Stage II-IIISpain
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedBreast CancerUnited States
-
Herbert Irving Comprehensive Cancer CenterUnknownOvarian Cancer | Fallopian Tube Cancer | Endometrial Cancer | Primary Peritoneal Cavity CancerUnited States
-
Hope Cancer Institute, Inc.UnknownLung CancerUnited States
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI)CompletedEsophageal CancerUnited States, Puerto Rico, South Africa
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)TerminatedCervical CancerUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedOvarian Cancer | Peritoneal Cavity CancerUnited States